Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2016 (2016), Article ID 3989070, 3 pages
http://dx.doi.org/10.1155/2016/3989070
Case Report

Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases

1Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, 34912 Istanbul, Turkey
2Marmara University School of Medicine, Department of Pediatrics, Division of Pediatric Pulmonology, 34912 Istanbul, Turkey

Received 1 February 2016; Accepted 28 April 2016

Academic Editor: Lawrence Yamuah

Copyright © 2016 Sevliya Öcal Demir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. J. Walsh, E. J. Anaissie, D. W. Denning et al., “Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America,” Clinical Infectious Diseases, vol. 46, no. 3, pp. 327–360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. I. H. Bartelink, T. Wolfs, M. Jonker et al., “Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 1, pp. 235–240, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. Vifend: EPAR—Product Information. European Medicines Agency (EMA), 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002669/WC500144015.pdf.
  4. Label Information for VİFEND, NDA no. 021266, Highlight of prescribing information, US Food and Drug Administration (FDA), http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf.
  5. B. J. Kullberg, J. D. Sobel, M. Ruhnke et al., “Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial,” The Lancet, vol. 366, no. 9495, pp. 1435–1442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ally, D. Schurmann, W. Kreisel et al., “A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients,” Clinical Infectious Diseases, vol. 33, pp. 1447–1454, 2001. View at Google Scholar
  7. L. B. Johnson and C. A. Kauffman, “Voriconazole: a new triazole antifungal agent,” Clinical Infectious Diseases, vol. 36, no. 5, pp. 630–637, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Purkins, N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans, “Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, pp. 2546–2553, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. D. I. Zonios, J. Gea-Banacloche, R. Childs, and J. E. Bennett, “Hallucinations during voriconazole therapy,” Clinical Infectious Diseases, vol. 47, no. 1, pp. e7–e10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Fernández-Ruiz, F. López-Medrano, E. Gutiérrez, and J. M. Aguado, “Complex visual hallucinations induced by voriconazole,” Medicina Clinica, vol. 133, no. 4, pp. 156–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Imhof, D. J. Schaer, U. Schwarz, and U. Schanz, “Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring,” Swiss Medical Weekly, vol. 136, no. 45-46, pp. 739–742, 2006. View at Google Scholar · View at Scopus
  12. M. J. Dolton, J. E. Ray, S. C.-A. Chen, K. Ng, L. G. Pont, and A. J. McLachlan, “Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 9, pp. 4793–4799, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Hamada, Y. Seto, K. Yago, and M. Kuroyama, “Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis,” Journal of Infection and Chemotherapy, vol. 18, no. 4, pp. 501–507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. E. H. Doby, D. K. Benjamin Jr., A. J. Blaschke et al., “Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children,” Pediatric Infectious Disease Journal, vol. 31, no. 6, pp. 632–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. E. Boyd, S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, and D. W. Denning, “Adverse reactions to voriconazole,” Clinical Infectious Diseases, vol. 39, no. 8, pp. 1241–1244, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. J. Walsh, P. Pappas, D. J. Winston et al., “Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever,” The New England Journal of Medicine, vol. 346, no. 4, pp. 225–234, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Pieper, H. Kolve, T. Meine, G. Goletz, and A. H. Groll, “Safety and outcome of treatment with voriconazole in a large cohort of immunocompromised children and adolescents,” GMS Infectious Diseases, vol. 3, article Doc01, 2015. View at Publisher · View at Google Scholar